May 17 (Reuters) - Moderna ... COVID shot Comirnaty after suing them in 2022 for allegedly copying its mRNA technology. Sign up here. Pfizer and BioNTech have countersued, alleging that Moderna's ...

Moderna said Friday that the European Patent ... rival COVID-19 vaccines. Cambridge-based Moderna has been fighting Pfizer and BioNTech in the courts over the partners’ COVID shot, called ...

When a novel respiratory virus emerged and sparked global worries, Moderna ... of the patent rights it is seeking to enforce relate to intellectual property created during its Covid-19 ...

said Wednesday it had achieved a “final victory” in a patent invalidation case against Moderna, the global developer of the messenger RNA (mRNA) Covid-19 vaccine. SK bioscience filed a nullity ...

The case is one of several brought by biotech companies seeking patent royalties from the blockbuster COVID-19 vaccines. Moderna earned $6.7 billion in revenue from its vaccine Spikevax last year ...

Appeals court affirmed that SM-102 does not infringe Alnylam’s mRNA patents. The decision supports Moderna’s use of SM-102 in its Spikevax COVID-19 vaccine. Live on Wednesday June 18: 3 Summer ...

Moderna said on May 17 that the European Patent Office had upheld the validity of one of the company’s key patents, a win in an ongoing Covid-19 vaccine dispute with Pfizer and BioNTech.

Moderna MRNA-Q said on Friday the European Patent Office had upheld the validity of one of the company’s key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer PFE-N and BioNTech ...

Moderna said that the European Patent Office had decided to maintain the validity of one of the company's key patents currently asserted against Pfizer and BioNTech in various European national ...